For Healthcare Professionals

Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine


About the study

Studies have shown that a broader spectrum influenza vaccine may help in reducing the influenza burden of disease. Butantan Institute is currently developing a quadrivalent influenza vaccine candidate. This study is will provide safety and immunogenicity data on this quadrivalent influenza vaccine candidate. The study will be conducted in an open population of healthy participants (3 years old and above) recruited in different clinical sites in Brazil and will be adequately powered to assess safety, immune response (measured by GMT HI antibodies) to each viral strain in the vaccines and lot-to-lot consistency.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Male or female, age 3 years or older at the time of enrollment.
  2. Provide written informed consent
  3. Agrees to complete all study visits, procedures and contacts
  4. Women and adolescents of childbearing age: Negative pregnancy test with understanding (through informed consent process).


Exclusion Criteria:

  1. Chronic medical conditions such as psychiatric conditions, diabetes, hypertension or any other conditions that might place the subjects at high risk of adverse events. Study clinicians will use clinical judgment on a case-by-case basis to assess safety risks under this criterion.
  2. Clinically significant abnormalities on physical examination.
  3. Use of immunosuppressive medications such as systemic corticosteroids or chemotherapeutics, or immunosuppressive illness.
  4. Women who are pregnant or planning to become pregnant during the study period plus 3 months beyond the last vaccine dose and currently nursing women.
  5. Participation in research involving another investigational product within 30 days before planned date of first vaccination or anytime through the last study safety visit.
  6. Clinically significant abnormalities on basic laboratory screening tests.
  7. Acute febrile illness (axillar temperature ≥ 37.8°C)
  8. Hypersensitivity to egg or chicken proteins or any of the vaccine constituents
  9. Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination
  10. Unstable chronic illness (defined as illness requiring hospitalization or a clinically significant change in medication in the previous 12 weeks).
  11. Alcohol abuse of alcohol or drug addiction
  12. Any vaccination within the previous 4 weeks
  13. Seasonal influenza vaccination in the current year

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Influenza, Human

Age (in years)



Phase 3

Participants needed


Est. Completion Date

Oct 18, 2024

Treatment type



Butantan Institute identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.